Gara Jalqabaatti › Dhukkuba Kroonii › North Carolina
Qorannoo klinikaalii Dhukkuba Kroonii North Carolina keessatti
Qorannoo 20 Dhukkuba Kroonii f North Carolina keessatti hirmaatuu jiru.
Magaalota North Carolina keessatti
Takkalaa qorannoo (Ingiliffa)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Partners /ID# 280490, Asheville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07697456A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- University of North Carolina at Chapel Hill, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Dubartoota · Haaromfame 05-Onk-2026 · NCT07654751A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of North Carolina Medical Center ( Site 5034), Chapel Hill
- Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 16 hanga 80 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
- Carolina Digestive Diseases, Greenville
- Piedmont Healthcare, Statesville
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina at Chapel Hill, Chapel Hill
- Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- OnSite Clinical Solutions-Site Number: 8400051, Charlotte
- Duke University Medical Center-Site Number: 8400093, Durham
- fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 16 hanga 80 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 16 hanga 80 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Cross Creek Medical Clinic, Fayetteville
- Peters Medical Research, High Point
- Wake Research Associates, Raleigh
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 85 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06226883A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina Hospital, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT07577843Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of North Carolina, Chapel Hill
- Atrium Health Center for Gastroenterology and Surgery, Charlotte
- Wake Forest School of Medicine, Winston-Salem
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT07237516Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
- University of North Carolina at Chapel Hill, Chapel Hill
Namoota walitti qabaa jira
Umuriin 18 hanga 44 · Dubartoota · Haaromfame 14-Ado-2026 · NCT07337902Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Univ NC Chapel Hill /ID# 262198, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 2 hanga 17 · Saalaa hunda · Haaromfame 24-Wax-2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Levine Children's, Charlotte
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 6 hanga 17 · Saalaa hunda · Haaromfame 27-Cam-2026 · NCT05781152COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health, Charlotte
- Duke Health System, Durham
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 1 hanga 18 · Saalaa hunda · Haaromfame 17-Elb-2026 · NCT07198113A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400003, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 27-Bit-2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, High Point
- Mirador Therapeutics Selected Site, Raleigh
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 12-Bit-2026 · NCT07113522Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Evidera, a PPD Business Unit /ID# 238688, Morrisville
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Dubartoota · Haaromfame 17-Ado-2025 · NCT04846959Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.